FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3017124984> ?p ?o ?g. }

• W3017124984 endingPage "260" @default.
• W3017124984 startingPage "254" @default.
• W3017124984 abstract "Pyrotinib, a novel irreversible pan-ErbB receptor tyrosine kinase inhibitor, showed promising antitumor activity and acceptable tolerability in phase II and phase III randomized clinical trials. We assessed the activity and safety of oral pyrotinib for human epidermal growth factor receptor 2 (HER2) positive metastatic breast cancer patients in the real world.We retrospectively analyzed 72 HER2 positive metastatic breast cancer (MBC) patients who received oral pyrotinib based regimens at Beijing Cancer Hospital and other four hospitals (Peking University First Hospital, China-Japan Friendship Hospital, General Hospital of PLA, Peking University Third Hospital) from August 2018 to September 2019. Progression free survival (PFS), objective response rate (ORR), adverse events (AE) of pyrotinib were investigated.Seventy-two patients with HER2 positive MBC were enrolled. The median age of the patients was 55 years (range: 32-79 years). Sixty-nine (95.8%) patients had received anti-HER2 treatment in the metastatic and/or (neo) adjuvant settings; 61 (84.7%) patients had received anti-HER2 treatments in the metastatic setting in terms of trastuzumab 56 (77.8%) patients, lapatinib 36 (50.0%) patients, and T-DM1 4 (5.6%) patients. Among these 72 patients who received oral pyrotinib based regimens, 62 (86.1%) patients received pyrotinib (±trastuzumab) in combination with chemotherapy, 6 (8.3%) patients received pyrotinib (± trastuzumab) in combination with endocrine therapy and 4 (5.6%) patients received pyrotinib (±trastuzumab). Sixty-five (90.3%) patients received 400 mg pyrotinib once daily as initial dose, and 7 (9.7%) patients received 320 mg. OBJECTIVE response and safety to pyrotinib based therapy were evaluable in all the 72 patients. One (1.4%) patient achieved complete response (CR), 18 (25.0%) patients achieved partial response (PR), 41 (56.9%) patients had stable disease (SD), and 12 (16.7%) patients had progressive disease (PD). The ORR (CR+PR) was 26.4% and the median PFS was 7.6 months (95%CI: 5.5-9.7 months). Among the 36 patients with prior lapatinib therapy, the median PFS was 7.9 months (95%CI: 4.1-11.7 months). Among the 15 patients with brain metastasis, the median PFS was 6.0 months (95%CI: 2.2-9.8 months). The main toxicities related to pyrotinib were diarrhea in 57 (79.2%) cases, and 48 (66.7%) cases with grade 1-2 as well as 9 (12.5%) cases with grade 3.Pyrotinib based therapy is an effective treatment for patients with HER2 positive MBC, including patients with lapatinib treatment failure and brain metastasis, and the toxicities can be tolerated." @default.
• W3017124984 created "2020-04-24" @default.
• W3017124984 creator A5005757964 @default.
• W3017124984 creator A5006293220 @default.
• W3017124984 creator A5008994723 @default.
• W3017124984 creator A5021016111 @default.
• W3017124984 creator A5024623595 @default.
• W3017124984 creator A5030453274 @default.
• W3017124984 creator A5031150824 @default.
• W3017124984 creator A5033265876 @default.
• W3017124984 creator A5045823020 @default.
• W3017124984 creator A5046262151 @default.
• W3017124984 creator A5059874513 @default.
• W3017124984 creator A5064957178 @default.
• W3017124984 creator A5076763144 @default.
• W3017124984 date "2020-04-18" @default.
• W3017124984 modified "2023-09-23" @default.
• W3017124984 title "[Efficacy and safety of oral pyrotinib in HER2 positive metastatic breast cancer: real-world practice]." @default.
• W3017124984 cites W1988737162 @default.
• W3017124984 cites W2062352315 @default.
• W3017124984 cites W2083308233 @default.
• W3017124984 cites W2110444464 @default.
• W3017124984 cites W2118600577 @default.
• W3017124984 cites W2127714076 @default.
• W3017124984 cites W2137673157 @default.
• W3017124984 cites W2141393790 @default.
• W3017124984 cites W2141546964 @default.
• W3017124984 cites W2148479421 @default.
• W3017124984 cites W2159967578 @default.
• W3017124984 cites W2165824128 @default.
• W3017124984 cites W2166199281 @default.
• W3017124984 cites W2318605753 @default.
• W3017124984 cites W2373297963 @default.
• W3017124984 cites W2613098450 @default.
• W3017124984 cites W2810920580 @default.
• W3017124984 cites W2947067095 @default.
• W3017124984 cites W2969604985 @default.
• W3017124984 cites W2990519743 @default.
• W3017124984 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7433442" @default.
• W3017124984 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32306007" @default.
• W3017124984 hasPublicationYear "2020" @default.
• W3017124984 type Work @default.
• W3017124984 sameAs 3017124984 @default.
• W3017124984 citedByCount "6" @default.
• W3017124984 countsByYear W30171249842021 @default.
• W3017124984 countsByYear W30171249842022 @default.
• W3017124984 countsByYear W30171249842023 @default.
• W3017124984 crossrefType "journal-article" @default.
• W3017124984 hasAuthorship W3017124984A5005757964 @default.
• W3017124984 hasAuthorship W3017124984A5006293220 @default.
• W3017124984 hasAuthorship W3017124984A5008994723 @default.
• W3017124984 hasAuthorship W3017124984A5021016111 @default.
• W3017124984 hasAuthorship W3017124984A5024623595 @default.
• W3017124984 hasAuthorship W3017124984A5030453274 @default.
• W3017124984 hasAuthorship W3017124984A5031150824 @default.
• W3017124984 hasAuthorship W3017124984A5033265876 @default.
• W3017124984 hasAuthorship W3017124984A5045823020 @default.
• W3017124984 hasAuthorship W3017124984A5046262151 @default.
• W3017124984 hasAuthorship W3017124984A5059874513 @default.
• W3017124984 hasAuthorship W3017124984A5064957178 @default.
• W3017124984 hasAuthorship W3017124984A5076763144 @default.
• W3017124984 hasConcept C121608353 @default.
• W3017124984 hasConcept C126322002 @default.
• W3017124984 hasConcept C143998085 @default.
• W3017124984 hasConcept C197934379 @default.
• W3017124984 hasConcept C2775930923 @default.
• W3017124984 hasConcept C2777329042 @default.
• W3017124984 hasConcept C2778375690 @default.
• W3017124984 hasConcept C2779786085 @default.
• W3017124984 hasConcept C530470458 @default.
• W3017124984 hasConcept C71924100 @default.
• W3017124984 hasConceptScore W3017124984C121608353 @default.
• W3017124984 hasConceptScore W3017124984C126322002 @default.
• W3017124984 hasConceptScore W3017124984C143998085 @default.
• W3017124984 hasConceptScore W3017124984C197934379 @default.
• W3017124984 hasConceptScore W3017124984C2775930923 @default.
• W3017124984 hasConceptScore W3017124984C2777329042 @default.
• W3017124984 hasConceptScore W3017124984C2778375690 @default.
• W3017124984 hasConceptScore W3017124984C2779786085 @default.
• W3017124984 hasConceptScore W3017124984C530470458 @default.
• W3017124984 hasConceptScore W3017124984C71924100 @default.
• W3017124984 hasIssue "2" @default.
• W3017124984 hasLocation W30171249841 @default.
• W3017124984 hasOpenAccess W3017124984 @default.
• W3017124984 hasPrimaryLocation W30171249841 @default.
• W3017124984 hasRelatedWork W1991018829 @default.
• W3017124984 hasRelatedWork W2169144202 @default.
• W3017124984 hasRelatedWork W2302523915 @default.
• W3017124984 hasRelatedWork W2338354381 @default.
• W3017124984 hasRelatedWork W2397992828 @default.
• W3017124984 hasRelatedWork W2420830960 @default.
• W3017124984 hasRelatedWork W2588964444 @default.
• W3017124984 hasRelatedWork W2919686750 @default.
• W3017124984 hasRelatedWork W2938276334 @default.
• W3017124984 hasRelatedWork W2944980276 @default.
• W3017124984 hasVolume "52" @default.
• W3017124984 isParatext "false" @default.
• W3017124984 isRetracted "false" @default.

• next